试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-25
Metformine and CC Compared With Placebo and CC for Induction Ovulation in PCOS Patients With Insulin Resistant
编号:NCT02523898登记状态:提前终止企业 / 申办者:Semnan University of Medical Sciences
药物 / 成分:metformine、placebo、clomiphene citrate
登记的停止原因(原文):unfortunately due to COVID 19and social problems following it,we were unable to reach the estimated sample size.Evantually we could have only 151 patients .
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-25
Carbidopa-Levodopa in Dry AMD With Geographic Atrophy
编号:NCT03451500登记状态:提前终止企业 / 申办者:Snyder, Robert W., M.D., Ph.D., P.C.
药物 / 成分:carbidopa-levodopa
登记的停止原因(原文):Lack of funding required for enrollment to reach statistical significance.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-25
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
编号:NCT03915405登记状态:提前终止企业 / 申办者:Kyowa Kirin, Inc.
药物 / 成分:KHK2455、Avelumab
登记的停止原因(原文):Termination was based on the business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-25
Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection
编号:NCT04341727登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:Hydroxychloroquine Sulfate、Azithromycin、Chloroquine Sulfate
登记的停止原因(原文):DSMB recommended study suspension slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-25
Abiraterone Acetate in Combination With Tildrakizumab
编号:NCT04458311登记状态:提前终止企业 / 申办者:Institute of Cancer Research, United Kingdom
药物 / 成分:Abiraterone Acetate、Tildrakizumab
登记的停止原因(原文):Funder decided that response outcomes to date did not support continuation of the study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-25
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
编号:NCT04808362登记状态:提前终止企业 / 申办者:Peptomyc S.L.
药物 / 成分:OMO-103
登记的停止原因(原文):Phase 1completed; sponsor decided to change strategy to a combination study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-25
FHD-286 in Subjects With Metastatic Uveal Melanoma
编号:NCT04879017登记状态:提前终止企业 / 申办者:Foghorn Therapeutics Inc.
药物 / 成分:FHD-286
登记的停止原因(原文):Sponsor terminated the study for business reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-25
Sciatica Epidural Radiculopathy Experimental New Interventional TherapY Clonidine Micropellet
编号:NCT05614648登记状态:提前终止企业 / 申办者:Sollis Therapeutics, Inc.
药物 / 成分:Clonidine Micropellets、Tuohy epidural needle
登记的停止原因(原文):Loss of funding- Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-24
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
编号:NCT02452970登记状态:提前终止企业 / 申办者:EpicentRx, Inc.
药物 / 成分:RRx-001、Gemcitabine and cisplatin
登记的停止原因(原文):Poor enrollment and adverse event experiences in the limited population
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-24
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
编号:NCT03597503登记状态:提前终止企业 / 申办者:Supernus Pharmaceuticals, Inc.
药物 / 成分:SPN-810、Placebo
登记的停止原因(原文):Business decision, not related to safety
查看官方原始记录 ↗